Full-Time

Accounting Manager

Jupiter Endovascular

Jupiter Endovascular

51-200 employees

Develops and sells endovascular cardiovascular devices

Compensation Overview

$155k - $180k/yr

+ Equity

Menlo Park, CA, USA

In Person

Bachelor's, Master's, MBA

Category
Accounting
Required Skills
NetSuite
Forecasting

Get referred to Jupiter Endovascular

See people who can refer or advise you

Requirements
  • 10+ years of progressive accounting experience, including at least 5 years in a managerial role with medical device industry experience
  • Bachelor’s degree in Accounting or Finance required; Master’s in Accounting/Finance or MBA preferred
  • CPA required with audit experience (Big 4 or comparable international public accounting firm preferred)
  • Strong technical accounting knowledge and experience preparing documentation for financial audits
  • Strong knowledge of financial reporting, budgeting, forecasting, planning, and variance analysis
  • Experience working in an early-stage environment scaling to a growth environment
  • Proficient with NetSuite
  • Familiarity with Sunshine Act reporting and regulatory compliance in medical devices
  • Exceptional leadership and communication skills to mentor teams and collaborate cross-functionally
  • Deep knowledge of US GAAP; experience with inventory/cost accounting in a manufacturing environment is a plus
  • ERP implementation experience is a plus
Responsibilities
  • Manage the end-to-end monthly, quarterly, and annual close processes, ensuring accurate and timely delivery of consolidated financial statements in accordance with US GAAP
  • Review journal entries, balance sheet reconciliations, and variance analyses prepared by the accounting team
  • Design, implement, and maintain internal control procedures over financial reporting to ensure compliance with SOX 404 requirements
  • Coordinate with external auditors to prepare for the company’s first independent financial audit including preparing PBC schedules and addressing technical accounting inquiries
  • Develop procedures for Sunshine Act reporting and other regulatory requirements
  • Optimize and automate accounting workflows within NetSuite ERP system and auxiliary financial tools to reduce close cycle times
  • Develop team members for career advancement
  • Perform other duties and special projects commensurate with the role

Jupiter Endovascular develops and sells advanced endovascular devices to improve cardiovascular health, serving hospitals and cardiovascular clinics worldwide. Its products are catheter-based tools used in endovascular procedures, developed, cleared by regulators, and clinically validated before being sold to healthcare providers. The company differentiates itself through a strong focus on clinical affairs and product management, plus a global market presence and strategic partnerships to broaden reach while prioritizing safety and proven efficacy. Its goal is to improve patient cardiovascular outcomes by delivering reliable, clinically validated endovascular solutions to healthcare providers around the world.

Company Size

51-200

Company Stage

Series B

Total Funding

$40M

Headquarters

Menlo Park, California

Founded

N/A

Get referred to Jupiter Endovascular

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Series B closed above $40 million on October 7, 2025, funding SPIRARE II and launch prep.
  • FDA cleared the Vertex Catheter in 2025, de-risking platform components for broader use.
  • Positive SPIRARE II results and new CMO strengthen partnering leverage before 2026 regulatory filings.

What critics are saying

  • Vertex remains investigational; U.S. and Europe commercial sales are blocked today.
  • SPIRARE II studied 123 patients; one disappointment with regulators can delay launch into 2027.
  • No public reimbursement, manufacturing scale, or post-market infrastructure exists; execution failure kills the company.

What makes Jupiter Endovascular unique

  • TFX decouples flexible navigation from stable support in pulmonary arteries.
  • Vertex Thrombectomy System delivered 39% RV/LV reduction and 100% technical success on May 20, 2026.
  • Jupiter hired interventional cardiologist Catalin Toma, MD, as CMO on August 13, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

Remote Work Options

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

22%

1 year growth

22%

2 year growth

22%
Cardiac Vascular News
Aug 13th, 2026
Jupiter Endovascular appoints catalin Toma, MD, as Chief Medical Officer.

Jupiter Endovascular appoints catalin Toma, MD, as Chief Medical Officer. More in financial: MENLO PARK, Calif.-(BUSINESS WIRE)- #TFX-Jupiter Endovascular appoints renowned interventional cardiologist Dr. Catalin Toma as Chief Medical Officer See full post here as originally published on this site

FinSMEs
Oct 7th, 2025
Jupiter Endovascular Closes Series B Funding

Jupiter Endovascular, a Menlo Park, CA-based medical technology startup, closed its Series B funding at over $40M

StockTitan
Oct 7th, 2025
Jupiter Endovascular Raises Over $40M Series B

Jupiter Endovascular closed an oversubscribed Series B financing round, surpassing its $40 million target. Led by Sonder Capital, with participation from Senvest Management, LB Investment, and a new strategic corporate investor, the funds will support the SPIRARE II clinical trial, commercialization, and new applications for its TFX technology. The Vertex Catheter with TFX recently received FDA 510(k) clearance, and SPIRARE I trial results will be presented at TCT 2025.

MD+DI
Oct 7th, 2025
Jupiter Endovascular Surpasses Funding Goal, Hits FDA Milestone

Jupiter Endovascular has raised over $40M in Series B funding led by Sonder Capital to advance its TFX platform and SPIRARE II trial.

MPO Magazine
Feb 26th, 2025
Jupiter Endovascular Hires Fred Ong as Finance Chief

Jupiter Endovascular revealed that experienced medtech finance and operations exec Fred Ong has joined the company as chief financial officer (CFO).